what is gout
the build up of uric acid crystals in the joints
what are the stages of gout
what illness can make people get gout
what are some predispositional factors to give someone gout
Inflammation in Gout:
Develops from hyperuricemia with uric acid crystals
Uric acid crystals stimulate:
Inflammatory signals
Activation of complement
Chemoattraction of neutrophils
Cytokines involved: IL-1, IL-6, TNF-α
Inflammasome, especially IL-1, implicated in gout onset
investigations for gout
Joint aspiration and polarized light microscopy for crystal detection
FBC: Raised WBC
ESR: Raised
X-ray: Normal in acute gout
Serum uric acid levels elevated (>10mg/L), but high levels don’t necessarily mean gout
Gout and Underlying Health Conditions:
Linked to conditions like hypertriglyceridemia, low HDL cholesterol, insulin resistance, obesity, hypertension
Gout-like symptoms can serve as a screening tool for underlying health problems
Treatment of Acute Gout Attacks:
Aims to reduce symptoms
Commonly used: NSAIDs, colchicine, prednisolone
NSAIDs at high doses (except aspirin)
Colchicine
Alkaloid preventing and relieving acute gout attacks
Blocks neutrophil migration, inflammatory glycoprotein production
Side effects: Gastrointestinal symptoms, toxicity at high doses
long term control of gout
Involves lifestyle changes and drug therapy
Common drugs: Xanthine oxidase inhibitors (allopurinol, febuxostat), uricosuric agents
Drug therapy not started during an attack but after settling
Allopurinol:
Allopurinol:
Drug of choice for long-term gout treatment
Reduces uric acid synthesis by inhibiting xanthine oxidase
Side effects: Mainly gastrointestinal, rare Stevens-Johnson syndrome
Not effective for acute attacks
Febuxostat:
Febuxostat:
Another xanthine oxidase inhibitor reducing uric acid levels
Side effects: Gastrointestinal symptoms, joint stiffness, headaches
Contraindicated with some chemotherapeutic drugs, costly
Other Gout Treatment Options:
Other Gout Treatment Options:
Uricosuric agents (sulfinpyrazone, benzbromarone)
Block uric acid reabsorption, increase excretion in urine
Biologics (canakinumab)
Target IL-1β pathways and P2X7 receptors